KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $39.5 million.

  • Amneal Pharmaceuticals' Other Non-Current Assets rose 877.76% to $39.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.5 million, marking a year-over-year increase of 877.76%. This contributed to the annual value of $60.1 million for FY2024, which is 831.46% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Other Non-Current Assets stood at $39.5 million, which was up 877.76% from $44.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $108.3 million during Q3 2022, with a 5-year trough of $19.2 million in Q2 2021.
  • In the last 5 years, Amneal Pharmaceuticals' Other Non-Current Assets had a median value of $60.1 million in 2024 and averaged $59.8 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Other Non-Current Assets soared by 45439.37% in 2022 and then tumbled by 5926.24% in 2024.
  • Amneal Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $20.6 million in 2021, then skyrocketed by 400.71% to $103.2 million in 2022, then crashed by 46.21% to $55.5 million in 2023, then rose by 8.31% to $60.1 million in 2024, then plummeted by 34.38% to $39.5 million in 2025.
  • Its last three reported values are $39.5 million in Q3 2025, $44.8 million for Q2 2025, and $45.4 million during Q1 2025.